

Shantha Biotech introduces Jencevac vaccine

10 May 2005 | News



Hyderabad-based Shantha Biotechnics has introduced Jencevac, a vaccine for combating Japanese Encephalitis (commonly known as brain fever) in the domestic market. Shantha Biotech has formed a partnership with Green Cross Vaccine Corporation, Korea, an international pharma company striving to provide worldwide prophylactic vaccines, for distribution and marketing of Jencevac in India.

Commenting on the launch, Varaprasad Reddy, managing director of Shantha Biotechnics, said "Jencevac is produced using the inactivated Nakayama strain known for its good propagation characteristics and its strength to provide cross-protection against other JE viral strains. With Jencevac, Shantha reiterates its dedication of providing excellent human healthcare products at affordable prices matched with good quality. JE vaccine is yet another step we have taken forward for fulfilling our mission of creating a healthy and ailment-free society."